Abstract：Ventricular arrhythmia is commonly seen in clinical practice. It is more common in patients with structural heart disease and can also occur in people without heart disease. Although more and more nondrug therapies have been emerging in recent years, antiarrhythmic drugs are still the basic and primary choice of treatment. Among the four major categories of antiarrhythmic drugs applied at present, β blockers is the only one which could reduce the total mortality rate. This paper evaluates its effectiveness on different kinds of ventricular arrhythmias.
[1] Pedersen CT, Kay GN, Kalman J. et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias[J]. Europace, 2014, 16(9)：1257-1283.[2] Priori SG, BlomstrmLundqvist C, Mazzanti A, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology(ESC)[J]. Eur Heart J, 2015, 36(41)：2793-2867.[3] Barsky AJ, Ahern DK, Bailey ED, et al. Predictors of persistent palpitations and continued medical utilization[J]. J Fam Pract， 1996， 42(5)：465-472.[4] Katritsis DG, Zareba W, Camm AJ. Nonsustained ventricular tachycardia[J]. J Am Coll Cardiol, 2012, 60(20)：1993-2004.[5] Paudel B, Paudel K. The diagnostic significance of the Holter monitoring in the evaluation of palpitation[J]. J Clin Diagn Res, 2013, 7(3)：480-483.[6] Yarlagadda RK, Iwai S, Stein KM, et al. Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract[J]. Circulation, 2005, 112(8)：1092-1097.[7] Bogun F, Crawford T, Reich S, et al. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention[J]. Heart Rhythm, 2007, 4(7)：863-867.[8] Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent STsegment elevation: the Task Force on the management of STsegment elevation acute myocardial infarction of the European Society of Cardiology[J]. Eur Heart J, 2008, 29(23)：2909-2945.[9] McMurray JJ,Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012：the Task Force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC[J]. Eur Heart J, 2012, 33(14)：1787-1847.[10] Westfall TC, Westfall DP. Adrenergic agonists and antagonists[M]//Brunton LL, Chabner BA，Knollmann BC. Goodman and Gilman’s the pharmacological basis of therapeutics. 12th ed. New York：McGrawHill, 2011：277-334. [11] Stec S, Sikorska A, Zaborska B, et al. Benign symptomatic premature ventricular complexes: short and longterm efficacy of antiarrhythmic drugs and radiofrequency ablation[J]. Kardiol Pol, 2012, 70(4)：351-358.[12] Krittayaphong R, Bhuripanyo K, Punlee K, et al. Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebocontrolled study[J]. Am Heart J, 2002, 144(6)：e10.[13] Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the cardiac arrhythmia suppression trial[J]. N Engl J Med, 1991, 324(12)：781-788. [14] Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH)[J]. Circulation, 2000, 102(7)：748-754. [15] Kosutic J, Prijic S, Kosutic I. Betablockers in pediatric cardiology[M]//Endo M, Matsumoto N. Betablockers: new research. New York: Nova Science Publishers Inc, 2008：75-105.[16] deSouza IS,Martindale JL,Sinert R. Antidysrhythmic drug therapy for the termination of stable, monomorphic ventricular tachycardia: a systematic review[J]. Emerg Med J, 2015, 32(2)：161-167.[17] Connolly SJ. Metaanalysis of antiarrhythmic drug trials[J]. Am J Cardiol, 1999, 84(9A)：90R-93R.[18] Steinberg JS, Martins J, Sadanandan S, et al. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators(AVID) study[J]. Am Heart J, 2001, 142(3)：520-529. [19] Connolly SJ, Dorian P, Roberts RS, et al. Comparison of betablockers, amiodarone plus betablockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators—the OPTIC Study: a randomized trial[J]. JAMA, 2006, 295(2)：165-171. [20] Seidl K, Hauer B, Schwick NG, et al. Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverterdefibrillator[J]. Am J Cardiol, 1998, 82(6)：744-748.[21] Kowey PR, Crijns HJ, Aliot EM, et al. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverterdefibrillator for prevention of implantable cardioverterdefibrillator interventions or death: the ALPHEE study[J]. Circulation, 2011, 124(24)：2649-2660.[22] 曹克将, 黄从新, 张澍, 等. 室性心律失常中国专家共识[J]. 中华心律失常学杂志, 2016, 20(4)：279-326.[23] Della Bella P, Baratto F, Tsiachris D, et al. Management of ventricular tachycardia in the setting of a dedicated unit for the treatment of complex ventricular arrhythmias: longterm outcome after ablation[J]. Circulation, 2013, 127(13)：1359-1368. [24] Nademanee K, Taylor R, Bailey WE, et al. Treating electrical storm:sympathetic blockade versus advanced cardiac life supportguided therapy[J].Circulation,2000,102(7)：742-747.[25] Deneke T, Lemke B, Mugge A, et al. Catheter ablation of electrical storm[J]. Expert Rev Cardiovasc Ther, 2011, 9(8)：1051-1058.
2017, Vol. 26 
